CN1265665A - 苯并咪唑衍生物 - Google Patents

苯并咪唑衍生物 Download PDF

Info

Publication number
CN1265665A
CN1265665A CN98807910A CN98807910A CN1265665A CN 1265665 A CN1265665 A CN 1265665A CN 98807910 A CN98807910 A CN 98807910A CN 98807910 A CN98807910 A CN 98807910A CN 1265665 A CN1265665 A CN 1265665A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
hydroxyl
aryl
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98807910A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·德拉奇
L·B·汤森
小F·L·波伊德
S·D·张伯林
S·M·达鲁格
D·N·德顿
M·W·安德森
G·A·弗雷曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
University of Michigan System
Original Assignee
Glaxo Group Ltd
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711982.0A external-priority patent/GB9711982D0/en
Priority claimed from GBGB9714552.8A external-priority patent/GB9714552D0/en
Application filed by Glaxo Group Ltd, University of Michigan System filed Critical Glaxo Group Ltd
Publication of CN1265665A publication Critical patent/CN1265665A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN98807910A 1997-06-10 1998-06-08 苯并咪唑衍生物 Pending CN1265665A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9711982.0A GB9711982D0 (en) 1997-06-10 1997-06-10 Benzimidazole derivatives
GB9711982.0 1997-06-10
GB9714552.8 1997-07-11
GBGB9714552.8A GB9714552D0 (en) 1997-07-11 1997-07-11 Benzimidazole derivatives

Publications (1)

Publication Number Publication Date
CN1265665A true CN1265665A (zh) 2000-09-06

Family

ID=26311687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98807910A Pending CN1265665A (zh) 1997-06-10 1998-06-08 苯并咪唑衍生物

Country Status (34)

Country Link
US (1) US6455507B1 (enExample)
EP (1) EP0994890B1 (enExample)
JP (1) JP4548866B2 (enExample)
KR (1) KR20010020465A (enExample)
CN (1) CN1265665A (enExample)
AP (1) AP1262A (enExample)
AR (1) AR012964A1 (enExample)
AT (1) ATE246700T1 (enExample)
AU (1) AU740792C (enExample)
BR (1) BR9810745A (enExample)
CA (1) CA2293470C (enExample)
CO (1) CO4970737A1 (enExample)
DE (1) DE69816992T2 (enExample)
DK (1) DK0994890T3 (enExample)
EA (1) EA002305B1 (enExample)
EE (1) EE9900564A (enExample)
ES (1) ES2205527T3 (enExample)
HR (1) HRP980303B1 (enExample)
HU (1) HUP0002224A3 (enExample)
ID (1) ID24054A (enExample)
IL (1) IL133285A0 (enExample)
IS (1) IS5285A (enExample)
MA (1) MA26504A1 (enExample)
MY (1) MY132872A (enExample)
NO (1) NO314847B1 (enExample)
NZ (1) NZ501415A (enExample)
OA (1) OA11230A (enExample)
PE (1) PE84099A1 (enExample)
PL (1) PL337773A1 (enExample)
PT (1) PT994890E (enExample)
SK (1) SK171499A3 (enExample)
TR (1) TR199903053T2 (enExample)
TW (1) TW565566B (enExample)
WO (1) WO1998056761A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160314B (zh) * 2005-02-22 2012-05-23 密执安州立大学董事会 Mdm2的小分子抑制剂以及其应用
CN119119151A (zh) * 2024-09-04 2024-12-13 斯坦德药典标准物质研发(湖北)有限公司 一种马立巴韦的制备方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990081940A (ko) 1996-01-23 1999-11-15 그레이엄 브레레톤, 레슬리 에드워즈 항바이러스제로서 변형된 벤즈이미다졸 누클레오시드
CA2297076A1 (en) 1997-07-30 1999-02-11 The Regents Of The University Of Michigan Lyxofuranosyl benzimidazoles as antiviral agents
DE19741715A1 (de) * 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
PT1368028E (pt) 2001-03-12 2007-11-26 Avanir Pharmaceuticals Compostos de benzimidazole para modulação de ige e inibição da proliferação celular
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2004261663A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
US20110070192A1 (en) * 2003-11-14 2011-03-24 Bruno Tse Method of preparation of novel nucleoside analogs and uses
DE102005019549A1 (de) * 2005-04-25 2006-12-14 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Diaminobenzimidazol
WO2007070947A1 (en) * 2005-12-22 2007-06-28 Alchemia Ltd Antibacterial agents
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US8338397B2 (en) 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
CN101821277B (zh) 2007-08-15 2014-05-07 Isis制药公司 四氢吡喃核酸类似物
WO2009100045A1 (en) * 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
EP2265627A2 (en) 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
AU2009296820B2 (en) 2008-09-26 2014-03-20 Merck Sharp & Dohme Llc Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8563746B2 (en) 2008-10-29 2013-10-22 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010091308A2 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US8536320B2 (en) 2009-02-06 2013-09-17 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
JP6005628B2 (ja) 2010-04-28 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
US8546344B2 (en) 2010-10-28 2013-10-01 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole
WO2014134493A1 (en) * 2013-03-01 2014-09-04 Los Alamos National Security, Llc Broad spectrum antibiotic compounds and use thereof
US9926556B2 (en) 2014-04-28 2018-03-27 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
WO2016089845A1 (en) * 2014-12-01 2016-06-09 Virginia Commonwealth University A convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction
RU2629670C2 (ru) * 2016-08-04 2017-08-31 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) 2-Амино-5,6-дифтор-1-(бета-D-рибофуранозил)-бензимидазол, способ получения и противовирусная активность его в отношении вируса герпеса простого 1-го типа
KR102583547B1 (ko) 2020-03-30 2023-10-06 (주)바이오메트릭스 테크놀로지 신규한 벤지미다졸 유도체, 이의 제조방법 및 이의 항암제 용도
EP3907230B1 (en) * 2020-03-30 2024-08-28 Biometrix Technology Inc. Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same
CN114096549A (zh) * 2020-06-23 2022-02-25 博美利克斯技术公司 新型苯并咪唑衍生物、其制备方法及其作为抗癌剂或者抗病毒剂的用途
KR102449266B1 (ko) 2020-06-23 2022-09-30 (주)바이오메트릭스 테크놀로지 항암 활성 그리고 항바이러스 활성을 갖는 신규한 벤지미다졸-탄수화물 결합체 화합물(Benzimidazole carbohydrate conjugate compound) 및 이의 제조 방법
KR102342313B1 (ko) 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1491244A (fr) 1966-03-09 1967-08-11 Nouveaux benzimidazoles solubles
FR1476350A (fr) 1966-04-18 1967-04-07 Yale & Towne G M B H Ferme-porte automatique à frein
US3655901A (en) 1970-07-30 1972-04-11 Merck & Co Inc Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles
DE2130030A1 (de) 1971-06-18 1972-12-21 Bayer Ag Fungizide und bakterizide Mittel
ES8101067A1 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
EP0304624A3 (de) 1987-07-29 1989-03-22 F. Hoffmann-La Roche Ag Benzimidazol-2-yl-pyridiniumverbindungen
IT1226100B (it) 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
EP0521463A3 (en) 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
GB9205071D0 (en) 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
AU5447094A (en) 1992-10-21 1994-05-09 Regents Of The University Of Michigan, The Polysubstituted benzimidazoles as antiviral agents
US5399580A (en) 1993-03-08 1995-03-21 Burroughs Wellcome Co. Therapeutic nucleosides-uses
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160314B (zh) * 2005-02-22 2012-05-23 密执安州立大学董事会 Mdm2的小分子抑制剂以及其应用
CN102627649A (zh) * 2005-02-22 2012-08-08 密执安州立大学董事会 Mdm2 的小分子抑制剂以及其应用
CN102627649B (zh) * 2005-02-22 2015-03-25 密执安州立大学董事会 Mdm2的小分子抑制剂以及其应用
CN119119151A (zh) * 2024-09-04 2024-12-13 斯坦德药典标准物质研发(湖北)有限公司 一种马立巴韦的制备方法

Also Published As

Publication number Publication date
HRP980303B1 (en) 2002-08-31
ATE246700T1 (de) 2003-08-15
KR20010020465A (ko) 2001-03-15
CO4970737A1 (es) 2000-11-07
AU8536098A (en) 1998-12-30
OA11230A (en) 2003-07-09
JP4548866B2 (ja) 2010-09-22
HRP980303A2 (en) 1999-04-30
US6455507B1 (en) 2002-09-24
PT994890E (pt) 2003-11-28
JP2002504105A (ja) 2002-02-05
TW565566B (en) 2003-12-11
IS5285A (is) 1999-12-06
EP0994890A2 (en) 2000-04-26
AU740792C (en) 2003-01-23
NO314847B1 (no) 2003-06-02
MY132872A (en) 2007-10-31
IL133285A0 (en) 2001-04-30
ID24054A (id) 2000-07-06
BR9810745A (pt) 2001-03-13
MA26504A1 (fr) 2004-12-20
PE84099A1 (es) 1999-09-24
AP9901707A0 (en) 1999-12-31
EA199901031A1 (ru) 2000-06-26
HUP0002224A3 (en) 2003-05-28
US20020094963A1 (en) 2002-07-18
DE69816992T2 (de) 2004-07-22
HUP0002224A1 (hu) 2001-04-28
HK1024921A1 (en) 2000-10-27
AU740792B2 (en) 2001-11-15
WO1998056761A2 (en) 1998-12-17
NO996086D0 (no) 1999-12-09
TR199903053T2 (xx) 2000-11-21
ES2205527T3 (es) 2004-05-01
CA2293470A1 (en) 1998-12-17
EA002305B1 (ru) 2002-02-28
CA2293470C (en) 2008-05-13
NZ501415A (en) 2001-10-26
SK171499A3 (en) 2000-08-14
EP0994890B1 (en) 2003-08-06
PL337773A1 (en) 2000-09-11
AP1262A (en) 2004-03-16
EE9900564A (et) 2000-06-15
AR012964A1 (es) 2000-11-22
NO996086L (no) 2000-02-09
DK0994890T3 (da) 2003-12-01
WO1998056761A3 (en) 1999-04-15
DE69816992D1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
CN1265665A (zh) 苯并咪唑衍生物
CN1166678C (zh) 嘌呤衍生物
CN1249074C (zh) 2－氨基羰基－9h－嘌呤衍生物
CN1268140A (zh) 单环l－核苷、类似物及其应用
CN1020107C (zh) 抗病毒化合物的制备方法
CN1159194A (zh) 治疗学化合物
CN100349913C (zh) 2′－氟代核苷
CN1466591A (zh) 核苷衍生物
CN87108265A (zh) 抗病毒化合物
CN1516590A (zh) 4′-取代的核苷
CN1400975A (zh) 嘌呤衍生物
KR20110104000A (ko) 우라실 사이클로프로필 뉴클레오티드
CN1871250A (zh) 用于治疗病毒感染的核苷化合物
JP2003513984A (ja) ２’−デオキシ−ｌ−ヌクレオシドの合成
KR20110038683A (ko) 사이클로프로필 폴리머라제 저해제
CN1214049A (zh) 治疗性化合物
JP2001512453A (ja) ベンゾイミダゾール誘導体
CN1420773A (zh) 5－(e)－溴乙烯基尿嘧啶类似物和相关的嘧啶核苷作抗病毒剂及其使用方法
CA2193665C (en) Benzimidazole derivatives for the treatment and prophylaxis of virus infections
HK1029998A (en) Monocyclic l-nucleosides, analogs and uses thereof
CZ448299A3 (cs) Benzimidazolové deriváty, způsob jejich výroby, farmaceutický prostředek obsahující tyto deriváty a použití těchto derivátů
CN1810822A (zh) 2－氨基羰基－9h－嘌呤衍生物
HK1024921B (en) Benzimidazole derivatives
HK1053842A (en) Purine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1055526

Country of ref document: HK